EX-DR TB EX-DR TB: Elimination of Extensive Drug Resistance Through better Regimens for TB
- Coordinator
- Ludwig-Maximilians-Universitaet Muenchen, Germany
- Runs
- 1 October 2025 to 30 September 2031
- Status
- Running
- EU funding
- €7.1m
- Total cost
- €7.1m
- Partners
- 17 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101190913
What the project is doing
In the project's own words, from its summary on CORDIS.
In 2022, the World Health Organization (WHO) recommended bedaquiline (BDQ)-based, all-oral regimens including pretomanid (Pa), linezolid (L), and moxifloxacin (M) (BPaLM), lasting 6-9 months However, BDQ-resistance is rising dramatically and threatening these advancements. Mozambique has reported BDQ resistance in 28% of MDR-TB isolates in 2024, up from 3% in 2016 and at 10% in South Africa (Ndjeka N, personal communication).
Spread of BDQ-R TB must be slowed by antibiotic stewardship through more rapid, accurate, and near-patient diagnostics, and optimized management; until new treatment options with drugs that have no pre-existing resistance or are able to overcome small shifts in MIC will be available. The proposed EX-DR TB project includes diagnostic capacity strengthening, adapting treatment recommendations, and a trial of two new regimens composed of new drugs.
The EDCTP EX-DR TB project will: 1.Develop treatment recommendations by a Delphi process with stakeholders - to make use of targeted next generation sequencing (tNGS) that is being rolled out by most national TB programmes - this will yield short-term benefit for patients and NTPs; and will slow the spread of BDQ-resistant bacteria;2.Rigorously evaluate two treatment regimens composed of new drugs, in a phase 3 clinical trial conducted to the highest regulatory standard – this will be the main focus of EX-DR TB.
The trial objective will be to move a regimen towards regulatory approval by FDA and/or EMA, and WHO if supported by results. Thus, EX-DR will create the tools for containing the nascent epidemic of BDQ-R TB and make them available to healthcare providers and TB Programmes. EX-DR TB will be embedded in a larger coalition of funders and partners focused on implementing and evaluating diagnostics and performing the trial beyond of the EDCTP funded area.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Coordinator |
| Forschungszentrum Borstel Leibniz Lungenzentrum | Borstel | Germany | Participant |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
| Glaxosmithkline Investigacion Y Desarrollo SL | Tres Cantos Madrid | Spain | Participant |
| Ospedale San Raffaele SRL | Milano | Italy | Participant |
| LigaChem Biosciences, Inc. | Daejeon | South Korea | Associatedpartner |
| Institutia Medico-Sanitara Publica - Institutul De Pneumologie ""chiril Draganiuc"""" | Chisinau | Moldova | Participant |
| Instituto Nacional de Saúde | Marracuene | MZ | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| Baylor College of Medicine Childrens Foundation Eswatini | Mbabane | SZ | Participant |
| City St Georges University of London | London | United Kingdom | Participant |
| University College London | London | United Kingdom | Participant |
| Global Alliance for Tb Drug Development Non Profit Organisation | New York | United States | Associatedpartner |
| The Regents of the University of California | Oakland | United States | Associatedpartner |
| University of Cape Town | Rondebosch | South Africa | Participant |
| Wits Health Consortium (pty) Ltd | Johannesburg | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI